van Haren, Simon D. http://orcid.org/0000-0002-1791-0161
Pedersen, Gabriel K.
Kumar, Azad
Ruckwardt, Tracy J. http://orcid.org/0000-0002-0007-7169
Moin, Syed
Moore, Ian N.
Minai, Mahnaz
Liu, Mark http://orcid.org/0000-0002-4048-2214
Pak, Jensen http://orcid.org/0000-0002-4455-7842
Borriello, Francesco
Doss-Gollin, Simon http://orcid.org/0000-0001-8797-7452
Beijnen, Elisabeth M. S. http://orcid.org/0000-0001-9359-7819
Ahmed, Saima
Helmel, Michaela
Andersen, Peter
Graham, Barney S.
Steen, Hanno http://orcid.org/0000-0003-0179-6648
Christensen, Dennis http://orcid.org/0000-0003-2382-8639
Levy, Ofer http://orcid.org/0000-0002-5859-1945
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U01AI124284-01, U19AI118608)
U.S. Department of Health & Human Services | DHHS Office of the Secretary (HHSN272201400052C)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (5T32HD055148-10)
Article History
Received: 28 January 2021
Accepted: 30 June 2022
First Online: 2 August 2022
Competing interests
: S.D.v.H., F.B. and O.L. are named inventors on patents describing early life vaccine adjuvant compositions. B.S.G. is named an inventor describing RSV prefusion F as a candidate vaccine. F.B. has signed consulting agreements with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Sana Biotechnology, Inc., and F. Hoffmann-La Roche Ltd. These commercial relationships are unrelated to the current study. The rest of the authors declare no competing interests.